Diy13 Emergent BioSolutions Overview Emergent BioSolutions (NYSE:EBS) has faced challenging circumstances, yet it is strongly positioned as an important player in public health. Earlier this year, I explored the high-risk, high-reward potential of EBS and its strategic turnaround efforts. Since then, significant strides have been made with its flagship product, NARCAN, which is central to the fight against the opioid crisis. Additionally, ACAM2000's potential expanded indication approval for monkeypox in Q3 ...